OptiBiotix health has signed a manufacturing, supply, and profit sharing deal with Sacco, one of Europe’s leading suppliers of probiotics ingredients.
Stephen O’Hara, CEO of OptiBiotix, said that Sacco was chosen for its industry reputation, European network and track record in building sales for probiotic strains.
O’Hara said: “We believe that OptiBiotix’s strong supporting science, and growing industry awareness of our LPLDL cholesterol and blood pressure reducing strain, has created a high level of interest in using LPLDL as a functional component in a wide range of consumer healthcare and pharmaceutical products. We believe working with Sacco, and similar partners around the world, provide the best opportunity of building LPLDL into a global brand. Discussions are progressing with corporate partners for the manufacture and supply of products containing LPLDL in the US, Asian and other international markets.”